Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China

(2020) Dawei Wang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

(2020) Kimiyasu Shiraki et al.   PHARMACOLOGY & THERAPEUTICS

Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance

(2020) Emi Takashita   Cold Spring Harbor Perspectives in Medicine

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

(2020)   Nature Microbiology

Dose Rationale for Favipiravir Use in Patients Infected With SARS‐CoV‐2

(2020) Philippine Eloy et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

(2020) Calvin J. Gordon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structure of replicating SARS-CoV-2 polymerase

(2020) Hauke S. Hillen et al.   NATURE

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

(2020) Yan Gao et al.   SCIENCE

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

(2020) Qingxian Cai et al.   Engineering

Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations

(2020) Mohamed Hagar et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Molecular pharmacology of ciclesonide against SARS-CoV-2

(2020) Hirokazu Kimura et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis

(2020) Rashidul Alam Mahumud et al.   INFECTION

The mechanism of resistance to favipiravir in influenza

(2018) Daniel H. Goldhill et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)—Sierra Leone, 2014

(2016) Chang-Qing Bai et al.   CLINICAL INFECTIOUS DISEASES

Computational protein–ligand docking and virtual drug screening with the AutoDock suite

(2016) Stefano Forli et al.   Nature Protocols

Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis

(2016) Aartjan J. W. te Velthuis et al.   NATURE REVIEWS MICROBIOLOGY

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

(2014) Lisa Oestereich et al.   ANTIVIRAL RESEARCH

Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model

(2014) Sophie J. Smither et al.   ANTIVIRAL RESEARCH

Integrating computational modeling and functional assays to decipher the structure-function relationship of influenza virus PB1 protein

(2014) Chunfeng Li et al.   Scientific Reports

Favipiravir elicits antiviral mutagenesis during virus replication in vivo

(2014) Armando Arias et al.   eLife

Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase

(2013) Hidehiro Sangawa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

(2009) Oleg Trott et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY